The immediate effects of one week of Delta Sleep-Inducing Peptide (DSIP) administration (6 X 30 nmol/kg b.w., i.v.) and late effects after a follow-up period of one week were investigated in a sleep laboratory study. The population of 18 chronic psychophysiological insomniacs was subdivided into two groups of middle-aged (29–59) and older (60–83) insomniacs. In the middle-aged insomniacs, improvement of sleep to normal values occurred by the end of DSIP administration and was maintained during the follow-up week. In the elderly insomniacs, who showed an initial sleep disturbance double as severe as the middle-aged group, the immediate effect was larger, but full normalization of sleep was only obtained by the end of the follow-up period. Although there was an interaction of sleep pathology and age, a regression analysis yielded clear evidence that the effects of DSIP were correlated to the degree of sleep disturbance. The whole sample of insomniacs showed normal sleep patterns at the end of the investigation.

Keywords:
DSIP, Treatment, Chronic insomnia, Elderly patients Normalization of sleep, Neuropeptide
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.